Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631236 · ClinicalTrials.gov registry record · NA
Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy
A NA study of Veteran Aged 65 and Older, sponsored by VA Office of Research and Development.
- Active
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 2
- Study locations
NCT05631236: Active NA study of Veteran Aged 65 and Older, sponsored by VA Office of Research and Development.
NCT05631236 is a NA study of Veteran Aged 65 and Older that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05631236, a NA study of Veteran Aged 65 and Older, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 2
- Study locations
Study Summary
Frailty is a multifactorial syndrome characterized by vulnerability to stressors that is intricately linked to cognitive impairment and mortality risk. Bright light therapy (BLT) reduces circadian disturbances by resynchronizing the hypothalamic biological clock via specific wavelengths of light. Human trials have demonstrated that BLT improves sleep quality and cognitive function in older adults. However, BLT has not been examined for use in older Veteran populations, particularly the impact on frailty. This randomized trial will assess the feasibility of employing BLT to study impacts on frailty, cognition, and sleep in older Veterans. Findings from this pilot will establish the power and effect size necessary for larger trials to support the use of BLT as readily available home-based treatment to improve healthspan of Veterans.
Primary Outcome
Sleep quality as assessed by Pittsburgh Sleep Quality Index (PSQI). The PSQI contains 19 self-rated questions that combined to form 7 component scores, each with a range of 0 to 3 points. These in turn are added to yield a global score with a range of 0 to 21 points. Higher scores indicate worse sleep quality.
Conditions Studied
Interventions
- DEVICE Bright Light Therapy (AYO Glasses)
Study Locations (2)
Missouri
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05631236 still lists
NCT05631236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Veteran Aged 65 and Older appearing as the primary indexed condition, and to 1 intervention - of which Bright Light Therapy (AYO Glasses) is the first listed.
NCT05631236 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05631236 about?
NCT05631236 is a clinical study titled "Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy". Frailty is a multifactorial syndrome characterized by vulnerability to stressors that is intricately linked to cognitive impairment and mortality risk. Bright light therapy (BLT) reduces circadian disturbances by resynchronizing the hypothalamic biological clock via specific wavelengths of light. Hu...
What is the current status of trial NCT05631236?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 43 participants. The study started on 2024-01-29. Estimated completion is 2026-06-30.
What conditions does trial NCT05631236 study?
This clinical trial studies the following conditions: Veteran Aged 65 and Older.
What interventions are being tested in trial NCT05631236?
The interventions under investigation include: Bright Light Therapy (AYO Glasses) (DEVICE).
Who is sponsoring clinical trial NCT05631236?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05631236 being conducted?
This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05631236's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI